Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CFO Scott Burrows sold 7,500 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $91.83, for a total transaction of $688,725.00. Following the sale, the chief financial officer owned 79,762 shares of the company’s stock, […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $92.01, for a total value of $1,380,150.00. Following the sale, the chief executive officer owned 537,540 shares in the company, valued […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) insider Heidy King-Jones sold 28,933 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $91.03, for a total value of $2,633,770.99. Following the sale, the insider owned 2,845 shares in the company, valued at approximately […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CFO Scott Burrows sold 17,500 shares of the business’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $89.89, for a total transaction of $1,573,075.00. Following the transaction, the chief financial officer owned 79,762 shares in the company, valued […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 1,051 shares of Stoke Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the sale, the insider directly owned 19,059 shares of the company’s stock, valued […]

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 16,141 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer directly owned 16,141 shares of the company’s […]

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 34,501 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total value of $932,217.02. Following the completion of the transaction, the chief executive officer directly owned 15,558 shares in […]

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $27.06, for a total transaction of $202,950.00. Following the completion of the sale, the insider directly owned 32,316 shares in the […]